Last reviewed · How we verify
BR1018B-1
BR1018B-1 is a small molecule that targets the renin-angiotensin system.
BR1018B-1 is a small molecule that targets the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | BR1018B-1 |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | ACE2 inhibitor |
| Target | ACE2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the angiotensin-converting enzyme 2 (ACE2) to reduce blood pressure and alleviate symptoms of heart failure.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR1018B-1 CI brief — competitive landscape report
- BR1018B-1 updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI